1. Home
  2. GHRS vs KOP Comparison

GHRS vs KOP Comparison

Compare GHRS & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • KOP
  • Stock Information
  • Founded
  • GHRS 2018
  • KOP 1988
  • Country
  • GHRS Ireland
  • KOP United States
  • Employees
  • GHRS N/A
  • KOP N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • KOP Forest Products
  • Sector
  • GHRS Health Care
  • KOP Basic Materials
  • Exchange
  • GHRS Nasdaq
  • KOP Nasdaq
  • Market Cap
  • GHRS 774.1M
  • KOP 680.9M
  • IPO Year
  • GHRS 2021
  • KOP 2006
  • Fundamental
  • Price
  • GHRS $11.94
  • KOP $28.76
  • Analyst Decision
  • GHRS Strong Buy
  • KOP Strong Buy
  • Analyst Count
  • GHRS 8
  • KOP 2
  • Target Price
  • GHRS $30.63
  • KOP $52.50
  • AVG Volume (30 Days)
  • GHRS 190.5K
  • KOP 167.4K
  • Earning Date
  • GHRS 11-13-2025
  • KOP 11-07-2025
  • Dividend Yield
  • GHRS N/A
  • KOP 1.11%
  • EPS Growth
  • GHRS N/A
  • KOP N/A
  • EPS
  • GHRS N/A
  • KOP 0.73
  • Revenue
  • GHRS N/A
  • KOP $1,992,600,000.00
  • Revenue This Year
  • GHRS N/A
  • KOP N/A
  • Revenue Next Year
  • GHRS N/A
  • KOP $1.74
  • P/E Ratio
  • GHRS N/A
  • KOP $39.34
  • Revenue Growth
  • GHRS N/A
  • KOP N/A
  • 52 Week Low
  • GHRS $6.00
  • KOP $22.99
  • 52 Week High
  • GHRS $20.50
  • KOP $39.83
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 34.28
  • KOP 44.81
  • Support Level
  • GHRS $13.71
  • KOP $27.38
  • Resistance Level
  • GHRS $14.59
  • KOP $28.98
  • Average True Range (ATR)
  • GHRS 0.76
  • KOP 0.95
  • MACD
  • GHRS -0.12
  • KOP 0.09
  • Stochastic Oscillator
  • GHRS 3.99
  • KOP 51.07

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

Share on Social Networks: